We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Bring photo ID to vote Check what photo ID you'll need to vote in person in the General Election on 4 July.
OFT closed case: Anticipated acquisition by Microsoft Corporation of Sybari Software Inc.
Francis Maude spoke to mark the third anniversary of the Cyber Security Strategy, announcing a cyber mentoring scheme and the 'Cryptoy' app.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
A new multi-million pound Microsoft package will ensure NHS systems have the most up-to-date software with the latest security settings.
A pharmacy-level recall of some valsartan-containing products took place due to possible contamination, including advice to healthcare professionals and information on supply. Letters were also sent about quadrivalent influenza vaccines and systemic and inhaled fluoroquinolones and an alert was issued...
(Sanofi Pasteur MSD) Some batches may have antigen levels below required specification – class 2 action within 38 hours. (EL (12)A/33)
Speech delivered by Karen Bradley on Tuesday 15 July at the America Square Conference Centre
Medicines have been taken out of the regulated medicines’ supply chain during distribution. The products have been parallel imported into the UK by Kosei Pharma, CST Pharma and Ordinant Medical Solutions from Italy and they have been re-labelled in Kosei...
Monitor patients for signs and symptoms of hypercalcaemia after discontinuation of denosumab treatment for giant cell tumour of bone. Cases of rebound hypercalcemia have been reported up to 9 months after cessation of treatment.
Letters were sent about quadrivalent influenza vaccine, fentanyl ampoules, and Volibris (ambrisentan), and a number of pharmacy-level recalls were issued for ranitidine-containing products. Other alerts issued in October 2019 are also summarised in this article.
Latest guidance from the National Cyber Security Centre (NCSC) about the 'WannaCry' malware.
Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.
Employment Tribunal decision.
Last month, letters were sent regarding SGLT2 inhibitors and Xgeva▼ (denosumab).
Includes: systemic anticancer treatment data published; measles vaccination advice; Cyclospora travel advice; report on syphilis.
Employment Tribunal Decision of Judge Hutchinson on 21 December 2016.
ACMD advice on Sativex, February 2013.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).